Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — The Food and Drug Administration released a slew of gene therapy policies Tuesday aimed at encouraging drug makers to bring more of the medicines to market and perhaps forcing them to lower their prices.

The FDA has approved just four gene therapies since 2017, and each has carried a sky-high price tag. The FDA’s most recent approval, AveXis’ Zolgensma, costs $2.1 million, the most expensive drug in history.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.